omadacycline (nuzyra) Report issue

Small molecule Approved FDA Fast Track FDA Priority Review FDA
AACT ChEMBL DrugBank Drugs@FDA MeSH PubChem

Active Ingredient History

NOW
  • Now
Omadacycline is a tetracyclin-derivative antibiotic, originated in Tufts University, and later co-developed by Merck and Paratek Pharmaceuticals. The drug was approved for treatment of community-acquired pneumonia, and for treatment of acute bacterial skin and skin structure infections. Omadacycline tosylate is available as tablets and in injectable form.   NCATS

Chemistry

  • SMILES: CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(cc(CNCC(C)(C)C)c(O)c4C(=O)C3=C(O)[C@]2(O)C(=O)C(=C1O)C(=O)N)N(C)C
  • InChIKey: JEECQCWWSTZDCK-IQZGDKDPSA-N
  • Mol. Mass: 556.66
  • ALogP: 1.32
  • ChEMBL Molecules:
    omadacycline  
    omadacycline tosylate  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$139.8350 - $270.2910
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

7-dimethylamino-9-(2,2-dimethylpropyl)aminomethylcycline | amadacyclin | amadacycline | omadacycline | omadacycline tosylate | ptk0796 | ptk 0796 | ptk-0796

Organizations (12)

Research & Development (12)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (19)

Approved Indications (2)


 

Pneumonia, Bacterial (approved 2018)

Staphylococcal Skin Infections (approved 2018)

Experimental Indications - Clinical Trial Phases 1-4 (18)


 

Bacterial Infections (Phase 3)

Bone Diseases, Infectious (Phase 2)

Community-Acquired Infections (Phase 3)

Cystic Fibrosis (Phase 4)

Cystitis (Phase 2)

Diabetes Mellitus (Phase 1)

Gastrointestinal Microbiome (Phase 4)

Healthy Volunteers (Phase 1)

Infections (Phase 2)

Mycobacterium Infections, Nontuberculous (Phase 2)

Pneumonia, Bacterial (Phase 3)

Pyelonephritis (Phase 2)

Respiratory Tract Infections (Phase 2)

Skin Diseases, Bacterial (Phase 2)

Skin Diseases, Infectious (Phase 3)

Soft Tissue Infections (Phase 3)

Urinary Tract Infections (Phase 2)

Wound Infection (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 18
  • # of Trial Organizations: 12

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue